LP
VTYX

LMR Partners’s Ventyx Biosciences VTYX Stock Holding History

LMR Partners’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$218K – 1637
2024
Q3 		$218K Buy
+100,000
New +$230K ﹤0.01% 977
2024
Q1 		– Sell
-460,800
Closed -$1.14M – 1327
2023
Q4 		$1.14M Buy
+460,800
New +$4.38M 0.01% 552

Other funds holding VTYX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

LMR Partners's VTYX Position: Q4 2024 in Review

LMR Partners sold out of Ventyx Biosciences (VTYX) in Q4 2024, closing a stake of 100,000 shares — an estimated $218K sold.

LMR Partners first reported a position in VTYX in Q4 2023 and held it in 2 quarters. The position peaked at $1.14M in Q4 2023. 124 funds tracked by Wall St. Rank hold VTYX as of Q4 2024.

  • LMR Partners reported no remaining Ventyx Biosciences position as of Q4 2024 after selling out during the quarter.
  • LMR Partners sold 100,000 Ventyx Biosciences shares in Q4 2024, an estimated $218K.
  • LMR Partners first reported a position in Ventyx Biosciences in Q4 2023 and held it in 2 quarters.
  • LMR Partners's Ventyx Biosciences position peaked at $1.14M in Q4 2023.
  • 124 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2024.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.